ZORYVE (roflumilast) cream 0.3% approved for plaque psoriasis in children ages 2+ (Jun 29 2026)
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (1/12/26) through T+5. Run-up high $30.2 on 1/12/26, low $19.5 on 5/21/26 (T-120 to T-1). FDA decision 6/29/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-06-29
OutcomeApproved
Drug / candidateZORYVE (roflumilast) Cream 0.3%
IndicationPlaque Psoriasis in Children Ages 2 to 5
CompanyArcutis Biotherapeutics
Market-cap tierMid
120-day run-up (T-120→T-1)-10.6%
Cohort decision-day move (history)±2% median
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier — history, not a prediction.